GEN - Genetic Engineering and Biotechnology News15h
StockWatch: Will BMS–2seventy Deal Prove a Win-Win?
Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...
The Pharma Letter20h
The week in pharma: action, reaction and insight – week to March 14
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...